Substance / Medication

Indinavir sulfate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The cleavage of indinavir sulfate: synthesis and characterization of a cis-1-amino-2-indanol salt.
Mokoto Tebogo M L, Lemmerer Andreas, Sayed Yasien et al. · Acta Crystallogr C Struct Chem · 2025
PMID: 40762275OtherFull text (PMC)
Desolvation behavior of indinavir sulfate ethanol and follow-up by terahertz spectroscopy.
Ito Masataka, Tokuda Reiko, Suzuki Hironori et al. · Int J Pharm · 2019
PMID: 31220565Other
Validation of a sensitive ion chromatography method for determination of monoethylsulfate in Indinavir sulfate drug substance.
Prasanna S John, Sharma Hemant Kumar, Mukkanti K et al. · J Pharm Biomed Anal · 2009
PMID: 19616913Other
Evaluation of an International Pharmacopoeia method for the analysis of indinavir sulfate by liquid chromatography.
Yekkala R, Lei H, Hoogmartens J et al. · J Pharm Biomed Anal · 2006
PMID: 16503105Other
Optimization and statistical evaluation of dissolution tests for indinavir sulfate capsules.
Carvalho-Silva B, Moreira-Campos L M, Nunan E A et al. · Farmaco · 2004
PMID: 15544798Other
Capillary electrophoretic method for determination of protease inhibitor indinavir sulfate used in human immunodeficiency virus therapy.
Aurora Prado María S, Kedor-Hackmann Erika R M, Santoro Maria Inês R M et al. · J Pharm Biomed Anal · 2004
PMID: 15013159Other
A five-year evaluation of reports of overdose with indinavir sulfate.
Lehman Heidi P, Benson Joan O, Beninger Paul R et al. · Pharmacoepidemiol Drug Saf · 2003
PMID: 14513658Other
Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients.
Kalaitzis Christos, Dimitriadis Georgios, Tsatidis Triantafylos et al. · Int Urol Nephrol · 2002
PMID: 12549631Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Indinavir sulfate (substance)
SNOMED CT
108696002
UMLS CUI
C0700483

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.